Please use this identifier to cite or link to this item:
|Title:||A review of three new anti-interleukin-5 monoclonal antibody therapies for severe asthma||Autores:||Agumadu, V. C.
González Mejías, Stephanie
|Researchers (UNIBE):||González Mejías, Stephanie||Affiliations:||Facultad de Ciencias de la Salud||Research area:||Ciencias de la Salud||Keywords:||Asthma; Monoclonal antibody||Issue Date:||2018||Publisher:||Cureus, Inc.||Source:||Cureus 10(8), e3216||Journal:||Cureus||Volume:||10||Issue:||8||Start page:||e3216||Abstract:||
Asthma is a chronic respiratory condition that is characterized by reversible airflow obstruction. Interleukin-5 (IL-5) is involved in the pathophysiology of the disease and drugs targeting IL-5 have been studied for years as a possible treatment option for severe asthma. In this review, the authors searched PubMed for major drug therapies and clinical trials against IL-5. A total of 29 articles met the criteria for selection and were shortlisted; of these, 10 papers were on benralizumab, 14 on mepolizumab, and five on reslizumab. The three drugs proved to be safe and efficacious for patients with severe asthma, leading to decreased rates of asthma exacerbations, lowered levels of eosinophils, and improved pulmonary functions in various studies. Patients also reported an improvement in the quality of life. The side effects of these three drugs were mild and no deaths directly linked to the drug were reported. However, longer duration studies are required to draw firm and strong conclusions on the safety of these therapeutic agents.
|Appears in Collections:||Publicaciones del Área de Salud - Medicina|
Show full item record Recommend this item
Files in This Item:
|1612428107.pdf||Full text [open acces]||138.31 kB||Adobe PDF||View/Open|
This item is licensed under a Creative Commons License